August 10, 2004 - Quintiles Transnational Corp. has completed the previously announced sale of assets relating to its specialty dermatology products company, Bioglan Pharmaceuticals, to BDY Acquisition Corp, a Delaware corporation and wholly owned subsidiary of Bradley Pharmaceuticals, Inc.

June 9, 2004 - Quintiles Transnational today announced that it has signed an agreement to sell assets relating to its specialty dermatology products company, Bioglan Pharmaceuticals, to New Jersey-based Bradley Pharmaceuticals, Inc., in a transaction valued at approximately $183 million in cash, plus direct costs for transferred inventory.